Fu Jen Today (25) stated that the new drug BRM424 for the treatment of neurotrophic keratitis (NK) has completed all dosing in Phase II clinical trials in the United States and Brazil. Safety has been good, and it is expected to release complete clinical data in the fourth quarter, striving to obtain authorization before the end of the year.